MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

Inicio・Lista de Acciones・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Cerrado

SectorSanidad

15.42 -1.6

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

14.88

Máximo

15.92

Métricas clave
By Trading Economics
Ingresos	13M -72M
Ventas	18M 38M
Margen de beneficios	-189.28
Empleados	270
EBITDA	20M -64M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+115.21% upside

Dividendos
By Dow Jones
Próximas Ganancias	4 nov 2025

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	458M 1.4B
Apertura anterior	17.02
Cierre anterior	15.42

Noticias sobre sentimiento de mercado

By Acuity

64%

36%

339 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

9.91 / 14.15 Soporte y Resistencia

Syndax Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

1 oct 2025, 18:59 UTC

Principales Movimientos del Mercado

Intel Shares Rise on Reported Talks to Add AMD as Customer

1 oct 2025, 23:47 UTC

Charlas de Mercado

Nikkei May Rise After Gains on Wall Street -- Market Talk

1 oct 2025, 23:45 UTC

Charlas de Mercado

Gold Edges Lower on Likely Technical Correction -- Market Talk

1 oct 2025, 23:12 UTC

Adquisiciones, fusiones, absorciones

Avalanche Treasury CEO is Bart Smith

1 oct 2025, 23:11 UTC

Adquisiciones, fusiones, absorciones

Avalanche Treasury Investors Include Dragonfly, VanEck, Galaxy Digital and Others

1 oct 2025, 23:07 UTC

Adquisiciones, fusiones, absorciones

Avalanche Treasury Plans to Own More Than $1B Worth of AVAX After Becoming a Public Company

1 oct 2025, 23:06 UTC

Adquisiciones, fusiones, absorciones

Avalanche Treasury Co. Has an Exclusive Relationship With Avalanche Foundation

1 oct 2025, 23:04 UTC

Adquisiciones, fusiones, absorciones

Avalanche Treasury: Transaction Includes About $460M in Treasury Assets

1 oct 2025, 22:41 UTC

Charlas de Mercado

Flight Centre Set for Calm Year After Turbulent FY 2025 -- Market Talk

1 oct 2025, 22:41 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

1 oct 2025, 22:34 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

1 oct 2025, 22:34 UTC

Charlas de Mercado

AGL Energy Is Less Risky Than the Market Thinks -- Market Talk

1 oct 2025, 22:25 UTC

Ganancias

Webco Industries 4Q EPS $9.18 >WEBC

1 oct 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

1 oct 2025, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

1 oct 2025, 20:33 UTC

Adquisiciones, fusiones, absorciones

Roche Begins Tender Offer for 89bio Pursuant to Previously Announced Merger Agreement

1 oct 2025, 20:30 UTC

Adquisiciones, fusiones, absorciones

Sherwin-Williams Completes $1.15B Purchase of BASF's Brazilian Architectural Paints Business

1 oct 2025, 20:20 UTC

Adquisiciones, fusiones, absorciones

These Stocks Moved the Most Today: Nike, Netflix, Fermi, Moderna, AES, Lithium Americas, Sunrun, Corteva, and More -- Barrons.com

1 oct 2025, 20:19 UTC

Adquisiciones, fusiones, absorciones

GPP Deal Includes Enel's Interests in Oklahoma, Minnesota and North Dakota Facilities

1 oct 2025, 20:16 UTC

Adquisiciones, fusiones, absorciones

GPP Buys All of Enel's Cash-Equity Interests in Five Operating Wind Facilities and Divests a Portion of Its Interests in Two Wind Facilities

1 oct 2025, 20:16 UTC

Adquisiciones, fusiones, absorciones

Harbert Management's Gulf Pacific Power Expands Operating Wind Portfolio in Transaction With Enel Green Power North America

1 oct 2025, 20:13 UTC

Adquisiciones, fusiones, absorciones

This Lithium Stock Is Soaring Again. How Government Money Is Giving It a Boost. -- Barrons.com

1 oct 2025, 20:04 UTC

Charlas de Mercado

Crude Oil Extends Losing Streak -- Market Talk

1 oct 2025, 19:49 UTC

Charlas de Mercado

Natural Gas Surges on Short-Covering Rally -- Market Talk

1 oct 2025, 19:30 UTC

Charlas de Mercado

Precious Metals Jump After Government Closes -- Market Talk

1 oct 2025, 18:15 UTC

Charlas de Mercado

Canada Tamps Down Talk of Dairy Trade Concessions -- Market Talk

1 oct 2025, 18:09 UTC

Charlas de Mercado

Ganancias

Nike and Adidas Duopoly is Back -- Market Talk

1 oct 2025, 18:08 UTC

Adquisiciones, fusiones, absorciones

These Stocks Are Moving the Most Today: Nike, Netflix, Fermi, Moderna, AES, Lithium Americas, Sunrun, Corteva, and More -- Barrons.com

1 oct 2025, 17:45 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

1 oct 2025, 17:45 UTC

Charlas de Mercado

Canadian House Prices Could Be in For Steady Stretch -- Market Talk

Comparación entre iguales

Cambio de precio

Syndax Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

115.21% repunte

Estimación a 12 Meses

Media 33.1 USD 115.21%

Máximo 56 USD

Mínimo 17 USD

De acuerdo con 12 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Syndax Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

12 ratings

Comprar

Mantener

Vender

De acuerdo con 12 analistas que ofrecen calificaciones bursátiles a para Syndax Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

9.91 / 14.15Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Sentimiento

By Acuity

339 / 371 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.